Armistice Capital Performance: Riding the Waves of Biotech Subsector Growth
Armistice Capital has carved out a distinctive niche in the dynamic realm of biotech investments, with its performance closely tied to strategic bets across various industry subsectors. Under the guidance of Steven Boyd, the firm has demonstrated a knack for...